E-viri
Recenzirano
Odprti dostop
-
Hoglund, Richard M; Pyae Phyo, Aung; Lek, Dysoley; Anvikar, Anupkumar R; Satpathi, Parthasarathi; Satpathi, Sanghamitra; Behera, Prativa Kumari; Tripura, Amar; Baidya, Subrata; Chau, Nguyen Hoang; Sovann, Yok; Mao, Sivanna; Oun, Savuth; Yen, Sovannary; Amaratunga, Chanaki; Saelow, Chalermpon; Runcharern, Ratchadaporn; Kaewmok, Weerayuth; Hanboonkunupakarn, Borimas; Mohanty, Akshaya Kumar; Heaton, James; Thant, Myo; Gantait, Kripasindhu; Ghosh, Tarapada; Amato, Roberto; Jacob, Christopher G; Gonçalves, Sónia; Waithira, Naomi; Grobusch, Martin P; van Vugt, Michele; Fairhurst, Rick M; Cheah, Phaik Yeong; Dhorda, Mehul; Maude, Richard J; Winterberg, Markus; Thuy-Nhien, Nguyen Thanh; Kwiatkowski, Dominic P; Jittamala, Podjanee; Lin, Khin; Chotivanich, Kesinee; Huy, Rekol; Ashley, Elizabeth; Mayxay, Mayfong; Newton, Paul N; Hien, Tran Tinh; Valecha, Neena; Smithuis, Frank; Faiz, Abul; Miotto, Olivo; Tarning, Joel; Day, Nicholas P J; White, Nicholas J; van der Pluijm, Rob W; Hoglund, Richard M; Phyo, Aung Pyae; ul Islam, Akhter; Anvikar, Anupkumar R; Satpathi, Parthasarathi; Behera, Prativa Kumari; Tripura, Amar; Baidya, Subrata; Onyamboko, Marie; Chau, Nguyen Hoang; Sovann, Yok; Sreng, Sokunthea; Oun, Savuth; Amaratunga, Chanaki; Chutasmit, Kitipumi; Saelow, Chalermpon; Hoa, Nhu Thi; Thanh, Ngo Viet; Hanboonkunupakarn, Borimas; Callery, James J; Heaton, James; Thant, Myo; Gantait, Kripasindhu; Ghosh, Tarapada; Woodrow, Charles J; Grobusch, Martin P; van Vugt, Michele; Fairhurst, Rick M; Cheah, Phaik Yeong; Peto, Thomas J; von Seidlein, Lorenz; Maude, Richard J; Winterberg, Markus; Kwiatkowski, Dominic P; Imwong, Mallika; Jittamala, Podjanee; Lin, Khin; Hlaing, Tin Maung; Chotivanich, Kesinee; Ashley, Elizabeth; Newton, Paul N; Hien, Tran Tinh; Faiz, Abul; Miotto, Olivo; Tarning, Joel; Day, Nicholas PJ; Dondorp, Arjen M
The Lancet (British edition), 04/2020, Letnik: 395, Številka: 10233Journal Article
Artemisinin and partner-drug resistance in Plasmodium falciparum are major threats to malaria control and elimination. Triple artemisinin-based combination therapies (TACTs), which combine existing co-formulated ACTs with a second partner drug that is slowly eliminated, might provide effective treatment and delay emergence of antimalarial drug resistance. In this multicentre, open-label, randomised trial, we recruited patients with uncomplicated P falciparum malaria at 18 hospitals and health clinics in eight countries. Eligible patients were aged 2–65 years, with acute, uncomplicated P falciparum malaria alone or mixed with non-falciparum species, and a temperature of 37·5°C or higher, or a history of fever in the past 24 h. Patients were randomly assigned (1:1) to one of two treatments using block randomisation, depending on their location: in Thailand, Cambodia, Vietnam, and Myanmar patients were assigned to either dihydroartemisinin–piperaquine or dihydroartemisinin–piperaquine plus mefloquine; at three sites in Cambodia they were assigned to either artesunate–mefloquine or dihydroartemisinin–piperaquine plus mefloquine; and in Laos, Myanmar, Bangladesh, India, and the Democratic Republic of the Congo they were assigned to either artemether–lumefantrine or artemether–lumefantrine plus amodiaquine. All drugs were administered orally and doses varied by drug combination and site. Patients were followed-up weekly for 42 days. The primary endpoint was efficacy, defined by 42-day PCR-corrected adequate clinical and parasitological response. Primary analysis was by intention to treat. A detailed assessment of safety and tolerability of the study drugs was done in all patients randomly assigned to treatment. This study is registered at ClinicalTrials.gov, NCT02453308, and is complete. Between Aug 7, 2015, and Feb 8, 2018, 1100 patients were given either dihydroartemisinin–piperaquine (183 17%), dihydroartemisinin–piperaquine plus mefloquine (269 24%), artesunate–mefloquine (73 7%), artemether–lumefantrine (289 26%), or artemether–lumefantrine plus amodiaquine (286 26%). The median age was 23 years (IQR 13 to 34) and 854 (78%) of 1100 patients were male. In Cambodia, Thailand, and Vietnam the 42-day PCR-corrected efficacy after dihydroartemisinin–piperaquine plus mefloquine was 98% (149 of 152; 95% CI 94 to 100) and after dihydroartemisinin–piperaquine was 48% (67 of 141; 95% CI 39 to 56; risk difference 51%, 95% CI 42 to 59; p<0·0001). Efficacy of dihydroartemisinin–piperaquine plus mefloquine in the three sites in Myanmar was 91% (42 of 46; 95% CI 79 to 98) versus 100% (42 of 42; 95% CI 92 to 100) after dihydroartemisinin–piperaquine (risk difference 9%, 95% CI 1 to 17; p=0·12). The 42-day PCR corrected efficacy of dihydroartemisinin–piperaquine plus mefloquine (96% 68 of 71; 95% CI 88 to 99) was non-inferior to that of artesunate–mefloquine (95% 69 of 73; 95% CI 87 to 99) in three sites in Cambodia (risk difference 1%; 95% CI −6 to 8; p=1·00). The overall 42-day PCR-corrected efficacy of artemether–lumefantrine plus amodiaquine (98% 281 of 286; 95% CI 97 to 99) was similar to that of artemether–lumefantrine (97% 279 of 289; 95% CI 94 to 98; risk difference 2%, 95% CI −1 to 4; p=0·30). Both TACTs were well tolerated, although early vomiting (within 1 h) was more frequent after dihydroartemisinin–piperaquine plus mefloquine (30 3·8% of 794) than after dihydroartemisinin–piperaquine (eight 1·5% of 543; p=0·012). Vomiting after artemether–lumefantrine plus amodiaquine (22 1·3% of 1703) and artemether–lumefantrine (11 0·6% of 1721) was infrequent. Adding amodiaquine to artemether–lumefantrine extended the electrocardiogram corrected QT interval (mean increase at 52 h compared with baseline of 8·8 ms SD 18·6 vs 0·9 ms 16·1; p<0·01) but adding mefloquine to dihydroartemisinin–piperaquine did not (mean increase of 22·1 ms SD 19·2 for dihydroartemisinin–piperaquine vs 20·8 ms SD 17·8 for dihydroartemisinin–piperaquine plus mefloquine; p=0·50). Dihydroartemisinin–piperaquine plus mefloquine and artemether–lumefantrine plus amodiaquine TACTs are efficacious, well tolerated, and safe treatments of uncomplicated P falciparum malaria, including in areas with artemisinin and ACT partner-drug resistance. UK Department for International Development, Wellcome Trust, Bill & Melinda Gates Foundation, UK Medical Research Council, and US National Institutes of Health.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.